Evidence map›Paper›PMID 40069746›Full record

ArticleBiotechnology for biofuels and bioproducts2025

Discovery of the antifungal compound ilicicolin K through genetic activation of the ilicicolin biosynthetic pathway in Trichoderma reesei.

Isabella Burger, Matthias Schmal, Kathrin Peikert, Lukas Fourtis, Christoph Suster, Christian Stanetty, Dominik Schnalzer, Barbara Hufnagel, Thomas Böttcher, Ruth Birner-Gruenberger and 4 more

Abstract read
In one paragraph

Article in Biotechnology for biofuels and bioproducts, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Draft genome sequence of mangrove-isolated fungusMicrobiology resource announcements · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Isabella BurgerInstitute of Chemical Technologies and Analytics, TU Wien, 1060, Vienna, Austria.
Matthias SchmalInstitute of Chemical, Environmental and Bioscience Engineering, TU Wien, 1060, Vienna, Austria.
Kathrin PeikertInstitute of Chemical, Environmental and Bioscience Engineering, TU Wien, 1060, Vienna, Austria.
Lukas FourtisInstitute of Chemical, Environmental and Bioscience Engineering, TU Wien, 1060, Vienna, Austria.
Christoph SusterInstitute of Applied Synthetic Chemistry, TU Wien, 1060, Vienna, Austria.
Christian StanettyInstitute of Applied Synthetic Chemistry, TU Wien, 1060, Vienna, Austria.
Dominik SchnalzerInstitute of Applied Synthetic Chemistry, TU Wien, 1060, Vienna, Austria.
Barbara HufnagelInstitute for Biological Chemistry & Centre for Microbiology and Environmental Systems Science, University of Vienna, 1090, Vienna, Austria.
Thomas BöttcherInstitute for Biological Chemistry & Centre for Microbiology and Environmental Systems Science, University of Vienna, 1090, Vienna, Austria.
Ruth Birner-GruenbergerInstitute of Chemical Technologies and Analytics, TU Wien, 1060, Vienna, Austria.
Robert L MachInstitute of Chemical, Environmental and Bioscience Engineering, TU Wien, 1060, Vienna, Austria.
Astrid R Mach-AignerInstitute of Chemical, Environmental and Bioscience Engineering, TU Wien, 1060, Vienna, Austria.
Matthias SchittmayerInstitute of Chemical Technologies and Analytics, TU Wien, 1060, Vienna, Austria. matthias.schittmayer@tuwien.ac.at.
Christian ZimmermannInstitute of Chemical, Environmental and Bioscience Engineering, TU Wien, 1060, Vienna, Austria. christian.zimmermann@tuwien.ac.at.

Funding

Austrian Science Fund 10.55776/COE7 (Cluster of Excellence microPlanet)Austrian Science Fund 10.55776/P 34036
6 · The paper itself

Abstract

backgroundGiven the global rise in antimicrobial resistance, the discovery of novel antimicrobial agents and production processes thereof are of utmost importance. To this end we have activated the gene cluster encoding for the biosynthesis of the potent antifungal compound ilicicolin H in the fungus Trichoderma reesei. While the biosynthetic gene cluster (BGC) is silent under standard cultivation conditions, we achieved BGC activation by genetically overexpressing the transcription factor TriliR.

resultsSuccessful activation was confirmed by RT-qPCR, proteomic and metabolomic analyses. Metabolomic profiling upon BGC expression revealed high-yield production of ilicicolin H. To elucidate the enzymatically highly diverse functionality of this BGC, we employed a combination of overexpression and deletions of individual genes in the BGC. While we hardly observed any of the previously reported side- or shunt products associated with heterologous ilicicolin H expression, we discovered that Trichoderma reesei produces a novel member of the ilicicolin family using a metabolomic molecular networking approach. This new compound, ilicicolin K, is expressed in substantial amounts in the genetically engineered Trichoderma reesei. Ilicicolin K differs from ilicicolin H in its structure by a second hydroxylation of the tyrosine derived phenol and an additional ring formed by an intramolecular ether bridge of the hydroxyl group at the pyridone towards the tyrosine moiety of the molecule. Bioactivity tests of ilicicolin K revealed a strong antifungal activity against Saccharomyces cerevisiae and a moderate activity against the human pathogen Candida auris, an emerging multi-drug resistant fungus.

conclusionsBy activating a silent BGC in T. reesei, we obtained a high-yielding strain for the production of the antifungal compounds ilicicolin H and the novel ilicicolin K. These two compounds share some structural properties and are thus highly likely to act on the fungal cytochrome bc1 complex, a component of the mitochondrial repository chain. However, they possess different bioactive properties, which might suggest that ilicicolin K may overcome certain limitations of ilicicolin H.

Indexed as

Antifungal agentsFungiMulti-omicsNatural productsPathway engineering

Identifiers

PMID40069746
PMCPMC11895301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.